This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wenzel, R. P. Articles by Karlowsky, J. A. Search for Related Content PubMed PubMed Citation Articles by Wenzel, R. P. Articles by Karlowsky, J. A.

In Vitro Susceptibilities of Gram-Negative Bacteria Isolated from Hospitalized Patients in Four European Countries, Canada, and the United States in 2000-2001 to Expanded-Spectrum Cephalosporins and Comparator Antimicrobials: Implications for Therapy

Virginia Commonwealth University, Richmond,¹ Focus Technologies, Herndon, Virginia²

Received 2 January 2003/ Returned for modification 18 June 2003/ Accepted 7 July 2003

Access to current antimicrobial agent surveillance data is an important prerequisite for the optimal management of patients with hospital-acquired infections. The present study used data collected in 2000 to 2001 from 670 laboratories in Europe (France, Germany, Italy, and Spain), Canada, and the United States to report on the in vitro activities of ceftriaxone, cefotaxime, and comparative agents against >125,000 isolates of gram-negative bacteria from hospitalized patients. All but two isolates of Enterobacteriaceae (one isolate of Proteus mirabilis from France and one isolate of Morganella morganii from Canada) were susceptible to imipenem. The susceptibility of Escherichia coli to ceftriaxone or cefotaxime was 97% in each country, and for P. mirabilis, susceptibility was 99% in each country except Italy. In contrast, susceptibility of E. coli to ciprofloxacin varied from 80.5% (Spain) to 94.0% (France); levofloxacin susceptibility ranged from 75.2% (Spain) to 91.6% (United States). Among Klebsiella pneumoniae and Klebsiella oxytoca isolates, ceftriaxone and cefotaxime susceptibilities ranged from 86.6 to 98.7% and 83.5 to 99.7%, respectively, depending upon the country. Considerable geographic variation in the susceptibilities (generally 85 to 95% susceptible) of Serratia marcescens and M. morganii to ceftriaxone and cefotaxime were observed. For S. marcescens, susceptibility to piperacillin-tazobactam varied from 81.5% (France) to 94.1% (Italy) and susceptibility to ciprofloxacin ranged from 66.2% (Germany) to 90.7% (Spain). Enterobacter cloacae and Enterobacter aerogenes were less susceptible to ceftriaxone and cefotaxime than were the other species of Enterobacteriaceae studied. The present study demonstrated that established parenteral expanded-spectrum cephalosporin antimicrobial agents retain significant in vitro activity against many clinically important gram-negative pathogens.

This article has been cited by other articles:

• Chastre, J., Luyt, C. E. (2007). Optimising the duration of antibiotic therapy for ventilator-associated pneumonia. ERR 16: 40-44 [Abstract] [Full Text]  
• Bizzarro, M. J, Dembry, L.-M., Baltimore, R. S, Gallagher, P. G (2007). Case-control analysis of endemic Serratia marcescens bacteremia in a neonatal intensive care unit. Arch. Dis. Child. Fetal Neonatal Ed. 92: F120-F126 [Abstract] [Full Text]  
• Bosso, J. A., Mauldin, P. D. (2006). Using Interrupted Time Series Analysis To Assess Associations of Fluoroquinolone Formulary Changes with Susceptibility of Gram-Negative Pathogens and Isolation Rates of Methicillin-Resistant Staphylococcus aureus.. Antimicrob. Agents Chemother. 50: 2106-2112 [Abstract] [Full Text]  
• Thiolas, A., Bollet, C., La Scola, B., Raoult, D., Pages, J.-M. (2005). Successive Emergence of Enterobacter aerogenes Strains Resistant to Imipenem and Colistin in a Patient. Antimicrob. Agents Chemother. 49: 1354-1358 [Abstract] [Full Text]  
• Poole, K. (2005). Aminoglycoside Resistance in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 49: 479-487 [Full Text]  
• Masterton, R. G., Kuti, J. L., Turner, P. J., Nicolau, D. P. (2005). The OPTAMA programme: utilizing MYSTIC (2002) to predict critical pharmacodynamic target attainment against nosocomial pathogens in Europe. J Antimicrob Chemother 55: 71-77 [Abstract] [Full Text]  
• (2003). Gram-Negative Bacteria and Broad-Spectrum Antibiotics: Good News Except for Fluoroquinolones. JWatch Infect. Diseases 2003: 7-7 [Full Text]